| Erin Elizabeth Mccarville, MD | |
|
1440 Duckwood Dr, Eagan, MN 55122-1451 | |
| (651) 406-8880 | |
| Not Available |
| Full Name | Erin Elizabeth Mccarville |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 1440 Duckwood Dr, Eagan, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194773291 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 43207 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Ridges Hospital | Burnsville, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Clinics | 7113830142 | 658 |
News Archive
A new anti-inflammatory compound developed at the University of California, Davis, acts as a "surge protector" to suppress inflammation and reduce cancer growth, at least in mouse models of cancer.
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.
The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.
› Verified 8 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
A new anti-inflammatory compound developed at the University of California, Davis, acts as a "surge protector" to suppress inflammation and reduce cancer growth, at least in mouse models of cancer.
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.
The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.
› Verified 8 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
A new anti-inflammatory compound developed at the University of California, Davis, acts as a "surge protector" to suppress inflammation and reduce cancer growth, at least in mouse models of cancer.
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.
The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Elizabeth Mccarville, MD 1440 Duckwood Dr, Eagan, MN 55122-1451 Ph: (651) 406-8880 | Erin Elizabeth Mccarville, MD 1440 Duckwood Dr, Eagan, MN 55122-1451 Ph: (651) 406-8880 |
News Archive
A new anti-inflammatory compound developed at the University of California, Davis, acts as a "surge protector" to suppress inflammation and reduce cancer growth, at least in mouse models of cancer.
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.
The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.
› Verified 8 days ago
Dr. Paul Anthony Karazija, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3400 Yankee Dr, R416, Eagan, MN 55121 Phone: 651-662-2566 | |
Laurie Jepson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3305 Central Park Village Dr Ste 200, Eagan, MN 55121 Phone: 651-406-8860 Fax: 651-688-7864 | |
Sajan Jiv Singh Nagpal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1185 Town Centre Dr Ste 205, Eagan, MN 55123 Phone: 612-871-1145 Fax: 612-870-5491 | |
Ashish K Tiwari, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1185 Town Centre Dr Ste 205, Eagan, MN 55123 Phone: 612-871-1145 Fax: 612-870-5491 | |
Sarah Mcintire, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1440 Duckwood Dr, Eagan, MN 55122 Phone: 651-406-8860 | |
Janine Pingel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1440 Duckwood Dr, Eagan, MN 55122 Phone: 651-406-8880 |